$TRVI News

Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target

Trevi Therapeutics, Inc. (TRVI) Analyst/Investor Day - Slideshow

Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target

Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23

Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript

Trevi Therapeutics Q1 2026 Earnings Call Transcript

Trevi Therapeutics Q1 EPS $(0.09) Misses $(0.07) Estimate

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Trevi Therapeutics: Late-Stage Transition Meets Execution Risk

What's Going On With Trevi Therapeutics Stock?

12 Health Care Stocks Moving In Friday's Pre-Market Session

Trevi Therapeutics shares are trading lower after the company announced the pricing of its $150 million offering of 11.6 million shares at $13 per share.

Trevi Therapeutics shares are trading lower after the company announced the pricing of its $150 million offering of 11.6 million shares at $13 per share.

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Reported Earlier, Trevi Therapeutics Prices $150M Offering Of 11.6M Common Shares At $13 Per Share For Haduvio Development

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Trevi Therapeutics shares are trading lower after the company announced a $150 million offering.

CORRECTION: Trevi Therapeutics Is Trading Lower

Trevi Therapeutics Commences $150M Common Stock Offering